The earnings call summary indicates mixed results. Basic financial performance shows positive cash flow and asset sales progress, but EBITDA decline in the tissue segment is concerning. Product development is promising with innovation plans, but market strategy is unclear due to potential tariff impacts. The shareholder return plan lacks detail on capital allocation priorities. Q&A insights reveal confidence in price hikes and asset sales without EBITDA erosion, but management's unclear responses on tariffs and asset mix raise uncertainties. Overall, the sentiment is neutral, balancing positive and negative factors.